Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
1.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
1.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

7.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
7.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SNHG10 promotes tumorigenesis through the EGFR/AKT/ERK/mTOR and miR-150-5p/VEGF-A axis, along with gemcitabine resistance in pancreatic ductal adenocarcinoma.

Cell death discovery·2026
Same author

Proteomics method for identifying POT1-associated complexes at telomeres using ChIP-Mass spectrometry.

Methods (San Diego, Calif.)·2026
Same author

Retraction Note: Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin.

Scientific reports·2025
Same author

Whole-exome sequencing for identification of specific gene mutations in an Indian cohort of triple-negative breast cancer patients.

Discover oncology·2025
Same author

Retraction Note: Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets.

Journal of hematology & oncology·2025
Same author

Cancer-associated transporters: Molecular drivers and drug delivery gateways.

Biochemical pharmacology·2025

Related Experiment Video

Updated: Apr 27, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

6.8K

LAMC2 as a therapeutic target for cancers.

Manoj Garg1, Glenn Braunstein, Harold Phillip Koeffler

  • 1Cancer Science Institute of Singapore (CSI), National University of Singapore , 14 Medical Drive, Singapore, 117599 , Singapore.

Expert Opinion on Therapeutic Targets
|July 1, 2014
PubMed
Summary

Laminin subunit gamma 2 (LAMC2) promotes cancer growth and spread by interacting with cell receptors. Targeting LAMC2 may offer new cancer therapies and diagnostic biomarkers.

Keywords:
AKTEGFRLAMC2adhesionbiomarkercancerinvasion

More Related Videos

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

1.3K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.9K

Related Experiment Videos

Last Updated: Apr 27, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

6.8K
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

1.3K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.9K

Area of Science:

  • Biochemistry and Molecular Biology
  • Cancer Biology and Therapeutics

Background:

  • Cancer remains a major global health challenge, impacting morbidity and mortality worldwide.
  • Laminins, key basal lamina proteins, regulate cell behavior, but cancer cells also utilize them for growth.
  • The laminin subunit gamma 2 (LAMC2) is implicated in various cancer progression mechanisms.

Discussion:

  • Elevated LAMC2 expression on cancer cells drives tumorigenesis via interactions with integrins (α6β4, α3β1) and EGFRs.
  • The LAMC2-mediated signaling network is crucial for cancer cell progression, migration, and invasion across multiple cancer types.
  • LAMC2's role highlights its potential as a therapeutic target for inhibiting tumor development.

Key Insights:

  • LAMC2 is a critical driver of cancer progression, influencing cell adhesion, migration, and survival.
  • Interactions between LAMC2 and cell-surface receptors are central to its pro-tumorigenic effects.
  • LAMC2 represents a promising target for novel anticancer strategies.

Outlook:

  • LAMC2-targeted therapies could offer new avenues for cancer treatment, aiming to inhibit tumorigenesis.
  • Elevated serum LAMC2 levels present a potential biomarker for cancer diagnosis and monitoring.
  • Further research into LAMC2 signaling pathways may uncover additional therapeutic and diagnostic applications.